Survodutide
Regulatory
Legal Status in 2026
In active US clinical trials (Phase 2 or later); no FDA approval yet.
This compound is under active investigation in US clinical trials (Phase 2 or later) and has not yet received FDA approval. It is not legally available for prescription or compounding outside of enrolled clinical trial settings. The risk-benefit profile is not yet established for the general population.
About
About Survodutide
Survodutide is a GLP-1/glucagon dual agonist developed by Boehringer Ingelheim and Zealand Pharma, in Phase III trials for obesity and non-alcoholic steatohepatitis (NASH). It has shown 18–19% weight loss in Phase II with particularly strong effects on liver fat reduction, making it a leading candidate for MASH/NASH treatment beyond weight loss. The glucagon component drives hepatic fat clearance while GLP-1 handles appetite and glycemic control.
Science
Mechanism of Action
Dual agonism at GLP-1 and glucagon receptors increases hepatic fat oxidation and lipolysis via glucagon signaling while GLP-1 receptor activation suppresses appetite and enhances insulin secretion in a glucose-dependent manner.
Dosing
Typical Protocol
0.6–4.8 mg subcutaneous injection once weekly; titrated over 16 weeks in Phase III protocols.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Availability
Provider availability
Survodutide is in active clinical trials and is not available through legitimate US prescribing or compounding channels outside an enrolled trial, so Vial does not list providers for it.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.